

A Phase 1, First-in-Human, Dose Escalation and Expansion Study to Evaluate the Safety and Tolerability of XmAb541 in Advanced Solid Tumors

Status: Recruiting

Eligibility Criteria

Sex: Male or Female

Age Group: 18 years and over

This study is NOT accepting healthy volunteers

Inclusion Criteria:

- ovarian, fallopian tube, peritoneal, endometrial, uterine, or another CLDN6-positive cancer that has returned, spread, or not responded to previous treatment - able to carry out most daily activities with limited assistance - see link to ClinicalTrials.gov for complete Inclusion Criteria

Exclusion Criteria:

- active autoimmune disease - significant heart, lung, or gastrointestinal disease - active hepatitis B or hepatitis C infection - see link to ClinicalTrials.gov for complete Exclusion Criteria

Conditions & Interventions

Conditions:

Cancer

Keywords:

Clinics and Surgery Center (CSC)

More Information

Description: This study is testing an investigational drug called XmAb541 for people with advanced solid tumors that test positive for a protein called CLDN6. XmAb541 is a type of immunotherapy designed to help the body's immune system recognize and attack cancer cells. The first part of the study will test different doses of XmAb541 to determine a safe and appropriate dose for future research. Once a recommended dose is identified, additional participants will receive that dose in the second part of the study. Researchers will evaluate the safety of XmAb541, how the body responds to the treatment, and whether it shows signs of helping to control or shrink cancer.

Study Contact: Melissa Geller - gelle005@umn.edu

Principal Investigator: Melissa Geller, MD

Phase: PHASE1

IRB Number: STUDY00025913

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.